2021年美国风湿病学会/血管炎基金会抗中性粒细胞胞质抗体相关血管炎管理指南
该指南由美国风湿病学会与血管炎基金会制定,针对GPA、MPA和EGPA的治疗管理提出基于证据的推荐。方法采用PICO格式构建临床问题,进行系统文献综述,并使用GRADE方法评估证据质量并形成推荐。最终为GPA/MPA提出26条推荐和5条未分级立场声明,为EGPA提出15条推荐和5条未分级立场声明,涵盖缓解诱导与维持治疗以及辅助治疗策略。
要点
- 重症GPA和MPA的缓解诱导与维持治疗推荐使用利妥昔单抗。
- 非重症EGPA推荐使用美泊利珠单抗。
- 所有推荐均为条件性推荐,部分因缺乏多项随机对照试验和/或低质量证据支持。
核心结论
- 该指南提出了首批由美国风湿病学会和血管炎基金会认可的抗中性粒细胞胞质抗体相关血管炎管理推荐。
- 指南为医疗专业人员治疗GPA、MPA和EGPA提供了指导。
研究设计与样本
- 临床问题以PICO格式构建,GPA/MPA有47个问题,EGPA有34个问题。
- 对每个PICO问题进行系统文献综述,采用GRADE方法评估证据质量并形成推荐。
- 每条推荐需投票面板至少70%的共识。
主要发现
- 为GPA/MPA提出26条推荐和5条未分级立场声明。
- 为EGPA提出15条推荐和5条未分级立场声明。
- 推荐涵盖GPA、MPA和EGPA的缓解诱导和维持治疗以及辅助治疗策略。
关键数值与推荐
- 重症GPA和MPA的缓解诱导和维持治疗推荐使用利妥昔单抗。
- 非重症EGPA推荐使用美泊利珠单抗。
- 所有推荐均为条件性推荐,部分因缺乏多项随机对照试验和/或低质量证据支持。
临床怎么用
- 临床医生可参照该指南对GPA、MPA和EGPA患者进行缓解诱导和维持治疗以及辅助治疗决策。
局限性
- 所有推荐均为条件性推荐,部分因缺乏多项随机对照试验和/或低质量证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. CONCLUSION: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
引用
- Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021. PMID: 34235894. doi:10.1002/art.41773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。